Section Arrow
MTSR.NASDAQ
- Metsera Inc
Quotes are at least 15-min delayed:2025/07/21 06:31 EDT
Pre Market
Last
 43.36
+0.65 (+1.52%)
Bid
43.15
Ask
44.14
High 46.97 
Low 42.83 
Volume 1272 
Regular Hours
Last
 42.71
-1.59 (-3.59%)
Day High 
47.4 
Prev. Close
44.3 
1-M High
46.43 
Volume 
684.19K 
Bid
43.15
Ask
44.14
Day Low
41.68 
Open
44.38 
1-M Low
24.83 
Market Cap 
4.65B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 37.25 
20-SMA 32.81 
50-SMA 29.84 
52-W High 47.4 
52-W Low 12.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.53/--
Enterprise Value
4.65B
Balance Sheet
Book Value Per Share
4.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.01 -0.27 -11.84%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.495 -0.58 -4.12%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.19 +0.35 +5.99%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.03 +0.11 +1.86%
Quotes are at least 15-min delayed:2025/07/21 06:31 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.